Neogen Chemicals Ltd Q4 FY2022 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/t6hgzudnf7wv8t4uc3bexncq.pdf

Key Takeaways


Lithium: Supply Advantage, Price Risk & Pass-Through

Dr. Harin Kanani: "This is uncharted territory. Lithium prices have never gone so high, not by a close margin. It is going to be interesting for us to see."

Revenue Growth & the Dahej Ramp

Dr. Harin Kanani: "At least, Neogen's customers are very happy that Neogen has lithium and their production has not stopped because Neogen is not able to supply lithium."

Margin Dynamics

Dr. Harin Kanani: "Our absolute number will keep increasing, but when you look at percentage margin, it could show some decrease because of this lithium price. That is something which we will have to basically keep in mind especially this year."

CAPEX & Capacity Expansion


Lithium-Ion Battery Strategy


Balance Sheet & Working Capital

Dr. Harin Kanani: "So far, we have not been able to deliver both very high growth as well as cash. So we will keep improving on that."

Guidance & Commitments

CommitmentSpecificsTimeline
Brownfield CAPEX completionAll expansions under the Rs. 150 crore CAPEX at Dahej SEZ completedBy June 2023
Incremental revenue from brownfieldRs. 250-300 crore per annum post-commissioningFull utilisation by FY25/FY26
FY24 revenue targetRs. 725-750 crore, assuming stable lithium prices (2017-2019 levels); revenue will overshoot if lithium stays elevatedFY24
EBITDA marginMaintain 18.5%, +/-1%; revisit crossing 20% only after FY24Ongoing through FY24
Revenue mix targetAdvanced intermediates at 40% of revenue, CSM at 20%By FY24
Electrolyte pilot plantOperationalThis year (FY23)
Dahej full utilisationRamp through new molecule launches in Q1/Q2By Q3/Q4 FY23, certainly by next year
Blended tax rate19-22% (narrower range) or 22-25% (broader range)Going forward
Electrolyte commercial CAPEXQuantum in thousands of MT; announcement contingent on customer clarity and commitmentNo timeline given

Key Metrics

MetricQ4 FY22
Revenue₹156.8 cr, +69% YoY
EBITDA₹26.6 cr, margin of 17%
PAT₹15.7 cr, +68% YoY
Organic Chemicals division growth+38% YoY
Inorganic Chemicals division growth+176% YoY
Domestic/export mix64% / 36%
Net Debt₹99 cr, vs ₹215 cr in previous year
Final dividend per share₹2.75 for FY22
Board-approved CAPEX for FY23Up to ₹150 cr at Dahej SEZ
Incremental revenue potential from brownfield expansions₹250-300 cr per annum post commissioning, full utilisation by FY25/FY26
Targeted revenue for FY24₹725-750 cr
Dahej utilisation level45-50%
EBITDA margin guidance18.5%, +/-1%
Blended tax rate anticipated19-22% (CFO) to 22-25% (broader range per MD)
Asset turn for new CAPEX~2x, slightly lower than usual 2-2.5x